Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Sponsor

Consorzio Oncotech (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT05833919

Collaborator

(none)

122

Enrollment

Locations

Arms

Anticipated Duration (Months)

4.9

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

GIM22-ERICA is a clinical trial investigating the efficacy of two different strategies in HER2 negative MBC treatment. The study will include MBC patients with histologically documented HER2 negative disease, who have progressed to one prior regimen for metastatic disease and are eligible for a second-line chemotherapy with either eribulin or capecitabine.

This study design should answer to different questions:

What is the correct placement of Eribulin in the context of a long term treatment strategy?
Is an early use of Eribulin the best approach for MBC pts treatment?
May early use of Eribulin impact on subsequent treatment outcomes?

The correlated biomarkers analysis, evaluating angiogenic, epithelial and mesenchymal markers should confirm the results observed in preclinical studies ad support the clinical findings. Liquid biopsies and ctDNA evaluation could help to monitor the course of the disease and to identify novel biomarkers of drug resistance.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Breast Cancer	Drug: Eribulin Mesylate Drug: Capecitabine	Phase 2

Detailed Description

Patients who are considered eligible for the study treatment, will be randomly allocated within the two study arms.

ARM A:

Second line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days
third line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days

ARM B:

Second line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days
Third line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days

Study treatment will be continued until disease progression, death, unacceptable toxicity, Investigator's decision or patient refusal of further treatment.

Study Design

Study Type:

Interventional

Actual Enrollment :

122 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

HER 2 negative MBC patients, who have progressed to a first line chemotherapy for metastatic disease and meet all the inclusion criteria, will be considered eligible for study enrollment. Patients will be randomly allocated using a 1:1 allocation centralized method into the two study arms: ARM A or ARM B. Randomization will be performed with a minimization procedure that will account for the following parameters as strata: center; ECOG Performance Status (0-1 vs 2); previous use of CDK inhibitor (yes vs no); previous use of bevacizumab (yes vs no); triple negative breast cancer (yes vs no).HER 2 negative MBC patients, who have progressed to a first line chemotherapy for metastatic disease and meet all the inclusion criteria, will be considered eligible for study enrollment. Patients will be randomly allocated using a 1:1 allocation centralized method into the two study arms: ARM A or ARM B.Randomization will be performed with a minimization procedure that will account for the following parameters as strata:center; ECOG Performance Status (0-1 vs 2); previous use of CDK inhibitor (yes vs no); previous use of bevacizumab (yes vs no); triple negative breast cancer (yes vs no).

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer (MBC) Patients: a Randomized Phase II Study - ERICA Trial

Actual Study Start Date :

Jul 30, 2018

Anticipated Primary Completion Date :

Jul 1, 2023

Anticipated Study Completion Date :

Jul 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: ARM A Second line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days followed by third line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days.	Drug: Eribulin Mesylate The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes. The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date Other Names: Eribulin Drug: Capecitabine Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
Experimental: ARM B Second line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days; followed by third line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days.	Drug: Eribulin Mesylate The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes. The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date Other Names: Eribulin Drug: Capecitabine Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.

Arm

Intervention/Treatment

Experimental: ARM A

Second line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days followed by third line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days.

Drug: Eribulin Mesylate

The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes. The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date

Other Names:

Eribulin

Drug: Capecitabine

Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.

Experimental: ARM B

Second line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days; followed by third line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days.

Drug: Eribulin Mesylate

Other Names:

Eribulin

Drug: Capecitabine

Outcome Measures

Primary Outcome Measures

Total Progression Free Survival (PFS-T) [62 months]
Total-progression-free survival (PFS-T) is defined as the time elapsed between randomization and the first event among the following: the date of progression after the second treatment on study -whichever the second treatment will be according to intention-to-treat (eventual departures from treatments planned in the protocol will be described) the date of death if death occurs before second progression Patients who are alive and who do not fall into any of the above categories at the end of the study will be censored on the date of the last information on vital status.

Secondary Outcome Measures

Overall Survival from the date of randomization [62 months]
This is defined as the time elapsed from the first day of 2nd line therapy and death
Health-related Quality of Life (QoL) [At screening and then every 8 weeks (including at the time of disease progression/s)]
Assessment will be performed by using EORTC QoL questionnaires (QlQ C30 and specific EORTC QlQ BR23)
Disease Control Rate [62 months]
Disease Control Rate (DCR: proportion of patients obtaining complete response or partial response or stable disease >= 6 months): in second line; In third line; In second and/or third line.
Post Progression Survival (PPS) [62 months]
This is defined as the time elapsed from disease progression after 3rd line of therapy and death;

Other Outcome Measures

Biomarker analysis on patients' blood samples [Baseline and 62 months]
Tumor Circulating DNA (ctDNA) Angiogenetic markers (VEGF, bFGF) EMT biomarkers (E- Cadherin, N-Cadherin, Vimentin, TGF-beta) Leukocyte-lymphocyte subpopulations Cytokines

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent (both for clinical and blood biomarker study)
Histological diagnosis of HER2 negative MBC
Females ≥ 18 years
Measurable disease (according RECIST criteria version 1.1)
Prior Anthracyclines and Taxanes in either (neo-) adjuvant or metastatic setting, unless the patient was not suitable for one of these treatments
1 prior cytotoxic regimen for advanced or MBC (not including adjuvant or neo-adjuvant therapy). Patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within 6 months of (neo-) adjuvant cytotoxic therapy that included anathracyclines and/or taxanes (see prior criteria);
Prior hormonotherapy and Cyclines inhibitors are allowed, so as indicated in the international guidelines for the management of hormone positive breast cancer (ER and/or PR positive);
ECOG Performance Status ≤ 2
Absence of angina or heart failure or infarction within 12 months from inclusion
Adequate bone marrow and organ function as follows (haemoglobin ≥9.0 g/dl; absolute neutrophil count ≥ 1.5x103/mm3; plateled count ≥ 100x103/mm3; bilirubin levels ≤ 1.5 times Upper Limits of Normal
biliary stenting is allowed to resolve obstruction - Serum Transaminase level ≤ 2.5 times ULN; serum creatinine ≤ 1.5 times ULN;
Life expectancy of at least 12 weeks;
If women of childbearing potential (WOCBP) age: effective contraceptive measures must be used during the study treatment period and up to 3 months after the last dose of study drug.

Exclusion Criteria:

Unability to give informed consent
Absence of measurable disease
Concurrent active malignancies (except of in situ carcinoma of the cervix and inactive non-melanoma skin cancer)
Current active infection;
Serious pre-existing medical conditions or serious concomitant diseases;
systemic disorders that would compromise the safety of the patient or her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris, or a clinically significant history of cardiac disease or uncontrolled diabetes mellitus);
Known immunodeficiency virus infection;
Pregnant or breastfeeding women
Unable to undergo medical test for geographical, social or psychological reason;
Active or symptomatic brain metastases;
Known complete Dihydropyrimidine dehydrogenase (DPD) deficiency (phenotype and/or genotype testing, according to applicable national guidelines, prior to the initiation of treatment with Capecitabine is recommended)
Recent or concomitant treatment with brivudine (there must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy).

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Fondazione Poliambulanza, Istituto Ospedaliero	Brescia	Italy	25124
2	A.R.N.A.S. Garibaldi - P.O. Nesima	Catania	Italy	95122
3	A.O. Pugliese-Ciaccio	Catanzaro	Italy	88100
4	A.O. S. Croce e Carle	Cuneo	Italy	12100
5	Ospedale Civile degli Infermi	Faenza	Italy	48018
6	Ospedale Fabrino Spaziani	Frosinone	Italy	03100
7	Ospedale Policlinico San Martino	Genova	Italy	16132
8	A.O. Ospedale Papardo	Messina	Italy	98158
9	AORN dei Colli - Ospedale Monaldi	Napoli	Italy	80131
10	Azienda Ospedaliero Universitaria Federico II	Napoli	Italy	80131
11	Istituto Nazionale dei Tumori - Fondazione G. Pascale	Napoli	Italy	80131
12	Università degli studi della Campania L. Vanvitelli	Napoli	Italy	80131
13	P.O. Santa Maria delle Grazie - ASL Napoli 2 Nord	Pozzuoli	Italy	80078
14	P.O. San Paolo - ASL Roma 4	Roma	Italy	00053
15	Università Campus Biomedico	Roma	Italy	00128
16	Policlinico Universitario Tor Vergata	Roma	Italy	00133
17	IFO - Istituto Nazionale Tumori Regina Elena - U.O.C. Oncologia Medica 1	Roma	Italy	00144
18	IFO - Istituto Nazionale Tumori Regina Elena - U.O.C. Oncologia Medica 2	Roma	Italy	00144
19	Ospedale Sandro Pertini - ASL Roma 2	Roma	Italy	00157
20	Fondazione Policlinico A. Gemelli	Roma	Italy	00168
21	Policlinico Universitario A. Gemelli	Roma	Italy	00168
22	Presidio Cassia Sant'Andrea - ASL Roma 1	Roma	Italy	00189
23	ASST Lariana - Ospedale Sant'Anna	San Fermo Della Battaglia	Italy	22020
24	ASUFC P.O. "Santa Maria della Misericordia"	Udine	Italy	33100
25	ASST Sette Laghi - Ospedale Di Circolo e Fondazione Macchi	Varese	Italy	21100

Sponsors and Collaborators

Consorzio Oncotech

Investigators

Study Chair: Mario R D'Andrea, MD, UOSD Oncologia, Presidio Ospedaliero San Paolo, Civitavecchia, Rome, Italy
Principal Investigator: Michelino De Laurentiis, MD, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Consorzio Oncotech

ClinicalTrials.gov Identifier:

NCT05833919

Other Study ID Numbers:

GIM22-ERICA

First Posted:

Apr 27, 2023

Last Update Posted:

Apr 27, 2023

Last Verified:

Apr 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Product Manufactured in and Exported from the U.S.:

Additional relevant MeSH terms:

Breast Neoplasms

Capecitabine

Study Results

No Results Posted as of Apr 27, 2023